The Microbiome Field Enters Its Next Chapter
New analytical tools and microbiome-based therapies are pushing the field beyond early hype toward clinical and scientific progress. The post The Microbiome Field Enters Its Next Chapter appeared first on GEN - Genetic Engineering and Biotechnology News .
The microbiome field is entering a new chapter, according to Sebastião van Uden, CEO of Bac3Gel. Scientists often struggle with inconsistent results from their own culture efforts, or are seeking solutions for bacteria that are difficult to grow. Bac3Gel offers a proprietary biomaterial platform made from food-grade ingredients, containing a synthetic organic gel that mimics human mucus.
This gel supports the growth of complex microbial communities, and can be customized for various environments like the gut, lung, skin, and vagina. Bac3Gel's technology addresses issues such as hard-to-culture bacteria, high costs, and low throughput of existing bioreactors. The company's three-step market strategy includes research tools, partnerships in the food supplement space, and development of live biotherapeutics.
Juan Sanchez, a product manager at Biolog, highlights Bac3Gel's PreBioM line of microplates, which are designed to simplify the study of human or animal gut microbiomes by testing their ability to metabolize various prebiotic substrates. The PreBioM microplates come pre-loaded with 90 different prebiotic substrates, removing the need for scientists to handle plate formulation and testing themselves. These microplates are applicable to other mammalian microbiomes like oral and skin.
Biolog's PreBioM plates are targeted towards scientists in universities, university hospitals, and pharmaceutical companies developing live biotherapeutics. This market is evolving towards more specialized products, requiring standardized media for producing live biotherapeutics. Biolog manufactures the media for growing bacteria used in live biotherapeutics, under true pre-reduced, anaerobically sterilized conditions with their TruPRAS product.
Siolta Therapeutics, co-founded by Nikole Kimes and Susan Lynch, aims to stop diseases before they start by using a cocktail of beneficial microbes to support immune tolerance in infants at risk of developing allergic diseases. Their research suggests that replenishing the gut microbiome can help support immune tolerance rather than immune inflammation. This innovative approach is part of the broader microbiome field's advancements, addressing key industry pain points and driving interest in customized media offerings.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
